Angus Dalgleish

British oncologist

Angus Dalgleish

FMedSci FRACP FRCP

Angus Dalgleish, March 2016

Born| May 1950 (age 73)[1]

Harrow, London, England

Alma mater| University College London
Employer| St George's, University of London
Known for| HIV/AIDS research[2]
Political party| UK Independence Party (UKIP)
Website| www.sgul.ac.uk/profiles/gus-dalgleish

Angus George Dalgleish (born May 1950) FRCP FRCPath FMedSci[2] is a professor of oncology at St George's, University of London, best known for his contributions to HIV/AIDS research.[3][4][5][6] Dalgleish stood in 2015 for Parliament as a UKIP candidate.

## Education[edit]

Angus George Dalgleish was born in May 1950 in Harrow, London.[1][7][8] Initially educated at the Harrow County School for Boys,[7] Dalgleish received a Bachelor of Medicine, Bachelor of Surgery degree from University College London with an intercalated bachelor's degree in Anatomy.[7]

## Career as medical researcher[edit]

After various positions in the United Kingdom, Dalgleish joined the Royal Flying Doctor Service in Mount Isa, Queensland, then progressed through positions at various hospitals in Brisbane, Australia, before moving to the Ludwig Institute for Cancer Research in Sydney.[7][8]

After completion of his training, Dalgleish returned to work in the UK in 1984 at the Institute of Cancer Research.[7][8] He is a co-discoverer of the CD4 receptor as the major cellular receptor for HIV.[9] [10][11][12] In 1986, he was appointed to a consulting position at Northwick Park Hospital, in 1991 he was made Foundation Professor of Oncology at St George's, University of London,[7] and in 1994 he was appointed Visiting Professor at the Institute of Cancer Research in London.[13]

In 1997, he founded Onyvax Ltd.,[1] a privately-funded biotechnology company developing cancer vaccines, where he held the position as Research Director;[14] it was dissolved in 2013.[15] Dalgleish is a member of the medical board in Bionor Pharma.[citation needed] Dalgleish is on the scientific advisory board of Immodulon, and has stock options in Immunor AS, a disclosure he made in order to have his research work published.[16][non-primary source needed]

During the COVID-19 pandemic, Dalgleish was criticised for being a proponent of the lab leak theory.[17]

## 2015 candidacy for Parliament[edit]

Dalgleish was a member of the UK Independence Party and stood as a candidate in Sutton & Cheam,[18][19] during the 2015 United Kingdom general election finishing fourth with 10.7% of the vote.[20] Dalgleish campaigned for Leave.EU[21] and appeared on the BBC Radio 4 Today programme presenting the case for Brexit.[22][18][23][24] He was an advocate of Leave Means Leave, a Eurosceptic group.[25]

## Awards and honours[edit]

Dalgleish was elected a Fellow of the Academy of Medical Sciences in 2001[2] and is also a Fellow of the Royal College of Physicians[when?] the Royal College of Pathologists[when?] and a Fellow of the Royal Australasian College of Physicians.[when?][23] His citation on election to FMedSci reads:

> Professor Angus Dalgleish is Professor of Oncology at St Georges Hospital Medical School London. He has made seminal observations relating to the virology of HIV. In particular he identified CD4 as a major receptive for HIV in humans, produced the first report of a link between Slim Disease in Africa and HIV infection. He also identified the close correlation between the immune response and the presence of tropical spastic paraparesis in patients infected with the HTLV-1 virus.[2]

## Bibliography[edit]

* Barnard, Paolo; Quay, Steven; Dalgleish, Angus (2021). The Origin of the Virus: The hidden truths behind the microbe that killed millions of people. Clinical Press Ltd. ISBN 978-1-85-457107-6.

## References[edit]

1. ^ a b c "Angus George DALGLEISH, born May 1950". London: Companies House, Government of the United Kingdom. Archived from the original on 5 July 2016.
2. ^ a b c d Anon (2001). "Professor Angus Dalgleish FMedSci". acmedsci.ac.uk. London: Academy of Medical Sciences. Archived from the original on 5 July 2016.
3. ^ Dalgleish, Angus; Whelan, M (2005). "Novel immunotherapeutic approaches to prostate cancer". Current Opinion in Molecular Therapeutics. 7 (1): 30–34. PMID 15732527.
4. ^ Dalgleish, Angus (1995). "HIV and CD26". Nature Medicine. 1 (9): 881–2. doi:10.1038/nm0995-881. PMID 7585208. S2CID 2132301.
5. ^ Stephen Ward; David Casey; Marie-Christine Labarthe; Michael Whelan; Angus Dalgleish; Hardev Pandha; Stephen Todryk (September 2002). "Immunotherapeutic potential of whole tumour cells". Cancer Immunology, Immunotherapy. 51 (7): 351–357. doi:10.1007/s00262-002-0286-2. PMID 12192534. S2CID 8959770.
6. ^ "Professor Angus Dalgleish". sgul.ac.uk. London: University of London. Archived from the original on 6 April 2016.
7. ^ a b c d e f "Angus Dalgleish Biography". St. George's University of London. Archived from the original on 16 June 2008. Retrieved 10 October 2008.
8. ^ a b c "Angus Dalgleish Biography". London Oncology Clinic. Archived from the original on 6 October 2008. Retrieved 10 October 2008.
9. ^ Dalgleish, Angus G.; Beverley, Peter C. L.; Clapham, Paul R.; Crawford, Dorothy H.; Greaves, Melvyn F.; Weiss, Robin A. (1984). "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus". Nature. 312 (5996): 763–767. Bibcode:1984Natur.312..763D. doi:10.1038/312763a0. PMID 6096719. S2CID 4349809.
10. ^ Wilks, David; Dalgleish, Angus (1992). Molecular and Cell Biology of Sexually Transmitted Diseases. Springer. p. 283\. ISBN 978-0-412-36510-2.
11. ^ "Biography". Hasumi International Research Foundation. Archived from the original on 21 November 2008. Retrieved 10 October 2008.
12. ^ Berridge, Virginia (1996). AIDS in the UK. Oxford University Press. p. 52\. ISBN 978-0-19-820473-2.
13. ^ Angus Dalgleish's publications indexed by the Scopus bibliographic database. (subscription required)
14. ^ "Corporate Fact Sheet" (PDF). Onyvax Ltd. Archived from the original (PDF) on 7 December 2004. Retrieved 10 October 2008.
15. ^ "ONYVAX LIMITED". Companies House Service. Retrieved 23 November 2019.`{{cite web}}`: CS1 maint: url-status (link)
16. ^ Sørensen, B.; Susrud, A.; Dalgleish, A.G. (2020). "Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity" (PDF). QRB Discovery. 1: e6. doi:10.1017/qrd.2020.8. PMC 7468800. PMID 34192262. S2CID 219811749.
17. ^ O'Neill, Sean (21 May 2021). "UK scientist feels vindicated as focus turns to Wuhan lab". The Times. Retrieved 19 January 2022.
18. ^ a b Angus Dalgleish (2015). "Angus Dalgleish: 2015 Parliamentary Candidate for Sutton & Cheam + Representative for Cheam". UKIP Sutton Borough. Archived from the original on 5 March 2016.
19. ^ Murphy-Pyle, Mike (4 March 2014). "Cancer expert Professor Angus Dalgleish to stand for UKIP in Sutton and Cheam". Sutton Guardian. Retrieved 29 April 2015.
20. ^ "UK Polling Report". ukpollingreport.co.uk.
21. ^ Anon (2016). "Is this doctor (and UKIP candidate) right that EU migrants will destroy the NHS?". The Guardian. London. Archived from the original on 22 April 2016.
22. ^ Roy Greenslade (2016). "Scientist complains to BBC about being misled over Radio 4 interview". The Guardian. London. Archived from the original on 1 July 2016.
23. ^ a b Angus Dalgleish (2016). "Consultant oncologist Angus Dalgleish". leave.eu. Archived from the original on 14 June 2016.
24. ^ Cressey, Daniel (2016). "Academics across Europe join 'Brexit' debate". Nature. 530 (7588): 15. Bibcode:2016Natur.530...15C. doi:10.1038/530015a. PMID 26842034.
25. ^ "Co-Chairmen – Political Advisory Board – Supporters". Leave Means Leave. Archived from the original on 24 October 2017. Retrieved 26 February 2018.

## External links[edit]

* Explosive study claims to prove Chinese scientists created COVID

Authority control

International|

* ISNI
* VIAF
* WorldCat

National|

* France
* BnF data
* Catalonia
* Germany
* Israel
* Belgium
* United States
* Netherlands

Academics|

* Scopus

Other|

* IdRef